Drug Type Small molecule drug |
Synonyms Dronedarone/ranolazine, Ranolazine/dronedarone |
Action antagonists, blockers |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), SCNA blockers(Sodium channel alpha subunit blockers), VDCCs blockers(Voltage-gated calcium channel blockers) + [2] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H45ClN2O5S |
InChIKeyDWKVCQXJYURSIQ-UHFFFAOYSA-N |
CAS Registry141625-93-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrial Fibrillation | Phase 2 | Germany | - | |
Atrial Fibrillation | Phase 2 | Italy | - | |
Atrial Fibrillation | Phase 2 | Israel | - | |
Atrial Fibrillation | Phase 2 | United States | - | |
Atrial Fibrillation | Phase 2 | Netherlands | - | |
Atrial Fibrillation | Phase 2 | United Kingdom | - | |
Atrial Fibrillation | Phase 2 | Poland | - |